Europe Intravenous Ibuprofen Market

Europe Intravenous Ibuprofen Market Size & Growth (2022 to 2027):

As per the research report, the size of the Europe Intravenous Ibuprofen Market was valued at USD 2.17 billion in 2022 and estimated to be growing at a CAGR of 19.23%, to reach USD 5.23 billion by 2027 during the forecast period 2022 to 2027.

The European intravenous ibuprofen market is anticipated to be driven by multiple factors over the forecast period. The main elements are the high prevalence of orthopedic disorders, more surgeries and neuromuscular diseases such as arthritis, increased cancer cases, growing urbanization, and increased demand for pain relievers.

In 2020, it reported the total number of surgeries performed in England and Wales to be over 3,102,600. In addition, over the several years, there has been a rise in hospitalization rate and development in medical devices, which increase the patient satisfaction rate. All these factors had increased the volume of surgical activity, which simultaneously is helping in driving the European intravenous ibuprofen market.

Some notable trends include the growing e-commerce sector, increasing healthcare spending, increased sports injuries and accidents, and medication awareness. According to the Royal College of Surgeons, around 4.2 million surgeries are performed in England's NHS. One study found that 80% of patients experienced severe pain after surgery. The development of intravenous formulation, such as ibuprofen, is helping patients recover better.

In 2019, Germany spent over USD 3,500 per capita on healthcare, making them the second-highest amount in the European region, 44% more than the average. In general, Germany spends a higher proportion of its GDP on health, averaging over 11.28%. Meanwhile, other European countries spend an average of 9.97% on healthcare. Although 84.58% of health expenditure is publicly funded, most of the share is through reimbursable policies.

However, the market's growth would be challenged by adverse side effects and an increase in the price of raw materials. In addition, careful doctor's assessment should be done considering the patient's risk factors, mainly for cardiovascular disorders, before starting long-term treatment, especially if high doses are needed. Risk factors that should assess include smoking, high blood pressure, diabetes, and high cholesterol, which are anticipated to harm the European intravenous ibuprofen market.

This research report on the Europe Intravenous Ibuprofen Market has been segmented and sub-segmented into the following categories:

By Age Group:

• Adults
• Paediatrics

By Indication:

• Fever
• Pain/inflammatory

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, due to improved health infrastructure and funds, the fastest-growing regional market in the United Kingdom, a large population coupled with increasing demand for intravenous ibuprofen due to increasing side effects of pain relievers such as respiratory depression, allergies, and delayed reflexes. In addition, there are vigorous research and development activities to develop innovative medicines to meet the high demand for chronic diseases treatments in the region.

In 2020, the annual public health expenditure in the United Kingdom represented 10.44% of GDP. It is a massive jump from the previous year and the highest proportion in the period considered. Around USD 200 billion was spent on healthcare in the UK in 2019. Broken down by sector, spent almost over USD 120 billion on the public services sector. Total spending continued to increase, despite decreasing expenditures as a percentage of GDP from 2010 to 2020.

 Due to high healthcare investments, France intravenous ibuprofen market will also have a steady growth rate during the analysis period. For instance, the region had a healthcare expenditure of 11.2% of its GDP during 2019.

KEY MARKET PLAYERS

Key players operating in the Europe Intravenous Ibuprofen Market profiled in this report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc., CSL Limited, Sandor Medicaids Pvt Ltd., Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., PT. Soho Industri Pharmasi, and Laboratorios Valmorca, C.A.,